Sökning: WFRF:(Key Timothy)
> (2009) >
Body weight and inc...
Body weight and incidence of breast cancer defined by estrogen and progesterone receptor status-A meta-analysis
-
- Suzuki, Reiko (författare)
- Karolinska Inst, Inst Environm Med, Div Nutr Epidemiol, S-17177 Stockholm, Sweden.;Univ Oxford, Canc Res UK Epidemiol Unit, Oxford, England.;Natl Canc Ctr, Res Ctr Canc Prevent & Screening, Div Epidemiol & Prevent, Chuo Ku, Tokyo 1040045, Japan.
-
- Orsini, Nicola (författare)
- Karolinska Institutet
-
- Saji, Shigehira (författare)
- Komagome Hosp, Div Clin Trials & Res, Tokyo Metropolitan Canc & Infect Dis Ctr, Tokyo, Japan.
-
visa fler...
-
- Key, Timothy J. (författare)
- Univ Oxford, Canc Res UK Epidemiol Unit, Oxford, England.
-
- Wolk, Alicja (författare)
- Karolinska Institutet
-
visa färre...
-
Karolinska Institutet Karolinska Inst, Inst Environm Med, Div Nutr Epidemiol, S-17177 Stockholm, Sweden;Univ Oxford, Canc Res UK Epidemiol Unit, Oxford, England.;Natl Canc Ctr, Res Ctr Canc Prevent & Screening, Div Epidemiol & Prevent, Chuo Ku, Tokyo 1040045, Japan. (creator_code:org_t)
- WILEY, 2009
- 2009
- Engelska.
-
Ingår i: International Journal of Cancer. - : WILEY. - 0020-7136 .- 1097-0215. ; 124:3, s. 698-712
- Relaterad länk:
-
https://onlinelibrar...
-
visa fler...
-
https://urn.kb.se/re...
-
https://doi.org/10.1...
-
http://kipublication...
-
visa färre...
Abstract
Ämnesord
Stäng
- Epidemiological evidence indicates that the association between body weight and breast cancer risk may differ across menopausal status as well as the estrogen receptor (ER) and progesterone receptor (PR) tumor status. To date, no meta-analysis has been conducted to assess the association between body weight and ER/PR defined breast cancer risk, taking into account menopausal status and study design. We searched MEDLINE for relevant studies published from January 1, 1970 through December 31, 2007. Summarized risk estimates with 95% confidence intervals (CIs) were calculated using a random-effects model. The summarized results of 9 cohorts and 22 case-control studies comparing the highest versus the reference categories of relative body weight showed that the risk for ER+PR+ tumors was 20% lower (95% CI = -30% to -8%) among premenopausal (2,643 cases) and 82% higher (95% CI = 55-114%) among postmenopausal (5,469 cases) women. The dose-response meta-analysis of ER+PR+ tumors showed that each 5-unit increase in body mass index (BMI, kg/m(2)) was associated with a 33% increased risk among postmenopausal women (95% CI = 20-48%) and 10% decreased risk among premenopausal women (95% Cl = -18% to -1%). No associations were observed for ER-PR- or ER+PR-tumors. For discordant tumors ER+PR- (pre) and ER-PR+ (pre/post) the number of cases were too small (<200) to interpret results. The relation between body weight and breast cancer risk is critically dependent on the tumor's ER/PR status and the woman's menopausal status. Body weight control is the effective strategy for preventing ER+PR+ tumors after menopause. (C) 2008 Wiley-Liss, Inc.
Ämnesord
- MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin -- Cancer och onkologi (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Clinical Medicine -- Cancer and Oncology (hsv//eng)
Nyckelord
- breast cancer
- body weight
- body mass index
- estrogen receptor
- progesterone receptors
- risk
Publikations- och innehållstyp
- ref (ämneskategori)
- art (ämneskategori)
Hitta via bibliotek
Till lärosätets databas